A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab

Conditions

• Colitis, Ulcerative
• Crohn Disease
• Inflammatory Bowel Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

Key Dates

First listed

Apr 15, 2026

Start date

Apr 13, 2026

Status verified

Jun 2026

Primary completion

Apr 10, 2029

Completion

Apr 10, 2029

Study Design

Enrollment

50 participants (estimated)

Arms

• Arm: Moderate-to-Severe Ulcerative Colitis (UC) or Crohn's Disease (CD)
  Participants with confirmed diagnosis of moderate-to-severe UC or CD treated with guselkumab as per standard clinical practice will be enrolled. No drug will be provided as part of this study. Only data available from standard clinical practice and medical records will be collected.

Primary Outcome Measure

Time to Guselkumab Persistence [ Time Frame: Up to Week 96 ]

Central Contacts

• Study Contact
  844-434-4210
  [email protected]

Find similar trials

Related Studies

• Immune Regulation in Ulcerative Colitis or Crohn s Disease
  Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
• A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
  Recruiting · University of California, San Francisco · San Francisco, California
• Gene Expression in Inflammatory Bowel Disease
  Enrolling By Invitation · Johns Hopkins University · Baltimore, Maryland
• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California